

## **UriCap Female complementary role in fighting Covid-19**

**In any healthcare or homecare setting, the UriCap Female decreases the number of necessary care interactions related to frequent diaper changes. Accordingly, UriCap Female can be recommended to be part of a strategy to prevent transmission of the Covid-19 virus for elderly female patients and staff alike.**



### **Highlights:**

UriCap Female is an innovative and proprietary **non-invasive (external) and leak-free urine collection device** designed for women by TillaCare Ltd, a biotechnology company based in Israel.

The UriCap Female was developed for incontinent elderly women in hospitals, homecare and long-term care centers. This group is currently at a high risk of being infected by Covid-19. The UriCap is particularly useful for women that suffer from urinary incontinence with partial immobility, that are sitting up or are bedridden using diapers or as an external alternative to catheters when urine monitoring is required.

The UriCap Female is replaced only once a day (vs. diapers which are replaced 4 -6 times/day), thereby decreasing staff and patient Covid-19 exposure and interactions. Accordingly, it may decrease the risk of Covid-19 virus spreading among this high-risk population. It mainly decreases the need for nighttime staff to change diapers and consequently also the need of PPE that is in short supply. For these and others reasons it would motivate staff to implement the UriCap in their care setting.

The UriCap Female device also improves the patient's quality of life by allowing a full night sleep without any diaper changes.

**The device is leak free and can also replace catheters for urine monitoring in intensive care situations. Reduction of catheter days are associated with less infections and by that shortening the time patients are required to stay in the hospitals.**



## **General Product Description:**

UriCap Female device is a non-invasive (external) and leak-free urine collection device designed to fit the female anatomy.

The device is for one-time use, adheres to the area around the urethra and attaches to a urine bag. It can be used in bed, sitting up and also for patients with some mobility.

## **Purpose and intended use:**

### **The UriCap female device is recommended for use in the following situations:**

- Urine collection due to immobility (intensive care, physical disabilities, unstable hydrodynamic condition, post-surgery)
- Monitoring of daily fluid balance w/o using a catheter
- Avoiding wetness in pelvic area postoperatively
- Improving skin condition

### **Advantages of UriCap Female for the patient:**

- An alternative to catheters and diapers
- Decreases the number of care instances
- Decrease catheter days (infection risk) in hospitals
- Supports a full night sleep without diaper changes
- Comfortable and keeps the skin dry
- Prevents unpleasant odors and maintains hygiene

### **Advantages for the caregiver:**

- Fast and easy to apply. [3D instruction movie](#).
- No sterile procedure needed
- Exchanged after 24 hours (daily)
- Improves workflow
- Less heavy lifting and improves workflow
- Enables non-invasive monitoring of urine
- Prevents excessive humidity, when treating burns, dermatitis and bed sores

### **UriCap Female benefits compared to existing solutions:**

- Both leak-free and external
- Made of soft and pliable Medical Grade Silicone
- Requires little space for disposal and storage
- No glue, tape, suction or other mechanical holders involved

### **\*Attached documents:**

- IFU - Instructions for Use
- Quick reference guide



### **Advantages of UriCap Female during Covid-19 times:**

- UriCap Female is **replaced only once a day** (vs. diapers 4 -6 times/day), that decreases the number of potential staff and patient Covid-19 exposures during the day, especially for elderly, which is the biggest high-risk group.
- **Fewer staff is needed.** In case of staff shortage, especially during night-time. The UriCap enables the care giver to maintain a high quality of care.
- **The device supports urine monitoring,** not possible with diapers and can also replace catheters for urine monitoring in intensive care situations. Reduction of catheter days are associated with less infections
- The UriCap Female device supports **a full night sleep** without diaper changes.

### **Regulatory Approvals:**

The UriCap is registered for:

- FDA registration class I
- CE registration class I
- AMAR (Israel)

### **Company Background:**

Tilla Care is an Israeli biotechnology company established in 2013 by Israeli and Swedish experts in medicine and technology who were disappointed with the lack of innovation and effective solutions for urine collection in chronic urine incontinence.

Tilla Care's mission is bringing to market innovative cutting-edge urine collection products mainly for incontinent men & women that dramatically reduces health risks, costs, and increases comfort as well as preventing social isolation.

The first product, UriCap Female, services a large need among the growing population of elderly women. We believe it will not only increase their dignity and health, but also decrease health care costs by preventing skin complications, reducing Urinary Tract Infections and the use of antibiotics.

The UriCap Female can be supplied in high numbers to centers or organizations implementing it in daily use.

## **References:**

The device has recently been introduced to the Israeli market (hospitals and geriatric centers).

The UriCap device has been tested and approved in a several Geriatric Medical Centers in Israel.

It has been in use, evaluated and distributed by AMT/Gordian Medical in the US to long-term care settings during the past 6 months.

Tillacare is willing to offer 10 devices free of charge for evaluation and training purposes in addition to training materials such as a video instruction, Webinars, training kit (silicone model) and RFQ.

Remote training sessions can also be offered.

## **Contact Manufacturer:**

### **TillaCare Ltd:**

**Website:** <https://www.tillacare.com>

### **Swedish office:**

Michael Cohn

CEO

Mobile: +46 70-787 7836

[michael@tillacare.com](mailto:michael@tillacare.com)

### **Israeli office:**

Hen Danieli

COO

[hen@tillacare.com](mailto:hen@tillacare.com)

Mobile: +972 54-970 0131

### **US Office:**

Greg Wright

US Business Director

[greg@tillacare.com](mailto:greg@tillacare.com)

Mobile: +1 (941) 350 7922

